In one of the first studies to evaluate both ANXA2 and S100A10 simultaneously in ovarian cancer, Lokman et al. [198] demonstrated that both ANXA2 and S100A10 are robust prognostic biomarkers in serous ovarian cancer. This evidence concerns the gene S100A10 and ovarian carcinoma.